The influence of ACE-inhibitor on endothelin concentration and some metabolic parameters in young hypertensives;Wpływ terapii ACE-inhibitorem na stȩżenie endoteliny i wybrane parametry metaboliczne u młodych osób z nadciśnieniem tȩtniczym

Polski Merkuriusz Lekarski

Volumn 21, Issue 122, 2006, Pages 174-176

  Bryl, Wiesław ^a,b   Pupek Musialik, Danuta ^a   Wańkowicz, Zofia ^c   Oko, Andrzej ^c   Litwin, Mieczysław ^c   Chrzanowski, Witold ^c   Nartowicz, Edmund ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Katedra i Klinika Chorob Wewnetrznych   (Poland)

^c AM ^*

Author keywords

Arterial hypertension; Endothelin 1; Trandolapril; Young hypertensives

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; TRANDOLAPRIL; INDOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HYPERTENSION; RADIOIMMUNOASSAY; BLOOD; CLINICAL TRIAL; FEMALE; MALE; METABOLISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; TREATMENT OUTCOME;

EID: 33748515929     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bakris G.L., Bhandaru S., Akerstrom V., i wsp.: ACE inhibitor mediated attenuation of mesangial cell growth. A role for endothelin. Am. J. Hypertens., 1994, 7, 583.
2. Cardillo C., Kilocoyne C.M., Waclawiw M., i wsp.: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension, 1999, 33(2), 753.
3. Horky K., Bultas J., Jachymova, i wsp.: Metabolic and humoral characteristics of normotensive offspring in a family with history of essential hypertension. Vnitr. Lek., 1993, 39(1), 4.
4. Horky K., Jachymova M., Jindra A., i wsp.: Metabolic, humoral and haemodynamic characteristics of normotensive offspring from hypertensive families. J. Hum. Hypertens., 1996, 10 Suppl 3, 85.
5. Hoffman A., Grossman E., Ohman P., i wsp.: Endothelin induces an initial increase in cardic output associated with selective vasodilation in rats. Life Sci., 1989, 45, 249.
6. Inoue A., Yanagisawa M., Kurihara H., i wsp.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci., USA, 1989, 86(8), 2863.
7. de Jongh S., Ose L., Szamosi T., i wsp.: Efficacy and Safety of Statin in Children With Familial Hypercholesterolemia. Circulation, 2002, 106, 2231-2237.
8. Kara-Perz H., Pupek-Musialik D.: Wpływ leczenia hipotensyjnego na stȩżenie endotelin w osoczu chorych na nadciśnienie tȩnicze samoistne. Nadciśnienie Tétnicze, 2000, T4, 1, 11.
9. Kohno M., Horio T., Ikeda M.: Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int., 1992, 42(4), 860.
10. Lerman A., Edwards B.S., Hallett J.W. i wsp.: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med., 1991, 997.
11. Levin E.R.: Endothelins. N. Engl. J. Med., 1995, 356.
12. Luscher T.F., Raij L., Vanhoutte P.M.: Endothelium dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension, 1987, 9, 157.
13. Macrae I.M., Mc Auley M.A. Robinson M.J.: Endothelin 1 induced hypertension. A consequence of medullary ischemia? J. Cardiovasc. Pharmacol., 1991, 17, S7, 496.
14. Neutel J.M., Smith D.H., Graettinger W.F.i wsp.: Heredity and hypertension: impact on metabolic characteristics. Am. Heart. J., 1992, 124(2), 435.
15. Schiffrin E. L., Tibault G.: Plasma endothelin in human essential hypertension. Am. J. Hypertens., 1991, 4, 303.
16. Schneider M.P., Hilgers K.F., Klingbeil A.U., i wsp.: Plasma endothelin is increased in early essential hypertension. Am. J. Hypertens., 2000, 13(6), 579.
17. Taddei S., Virdis A., Ghiadoni L., i wsp.: Effects of angiotensin converting enzyme inhibition endothelium-dependent vasodilation in essential hypertensive patients. J. Hypertens., 1998, 16, 447.
18. Uemasu J., Munemura C., Fujihara M., i wsp.: Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension. Clin. Nephrol., 1994, 41, 150.
19. Wilkins F.C., Kassab S., Kato T., i wsp.: Chronic endothelin-induced pressor and renal action in conscious dogs do not require altered ANG II formation. Am. J. Physiol., 1995, 268, 395.
20. Wimalasundera R.C., McG Thom S.A., Regan L., i wsp.: Action of the endothelin receptor (ETA) antagonist BQ-123 on forearm blood flow in young normotensive subjects. Clin. Sci., 2002, Jun, 102(6), 661.
21. Yanagisawa M., Kurihara H., Kimura S i wsp.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1998, 332, 411.
22. Yanagisawa M., Inoue T., Ishikawa T.: Primary structure, synthesis, and biological activity of rat endothelin an endothelium-derived vasoconstrictor peptide. Proc. Natl. Acad. Sci., 1988, 85, 6964.
23. Yokokawa K., Tahara H., Kohno M, i wsp.: Hypertension associated with endothelin-secreting malignant haemangioendothelioma. Ann. Intern. Med., 1991, 114, 213.
24. Yoshida H., Nakamura M.: Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. Life Sci., 1992, 50, PL 195.
25. Zasady postȩpowania w nadciśnieniu tȩtniczym: Nadciśnienie tȩtnicze, 2003, supl.B, A8.